Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Company Deals Digital

Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis

Fineline Cube Feb 25, 2026
Company Deals

YolTech Partners with XtalPi to Build AI‑Driven mRNA and CAR‑T Screening Platform – Closed‑Loop Dry‑Wet Lab Integration

Fineline Cube Feb 24, 2026
Company Deals

Frontier Biotech Licenses Two siRNA Assets to GSK in $1B+ Deal – Expands Global RNAi Partnership

Fineline Cube Feb 24, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic

Fineline Cube Feb 25, 2026
Company Drug

Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH

Fineline Cube Feb 25, 2026
Company

WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges

Fineline Cube Jul 30, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...

Company Deals

Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business

Fineline Cube Jul 30, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...

Company

Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand

Fineline Cube Jul 30, 2024

Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...

Company Deals

GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines

Fineline Cube Jul 30, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...

Company Drug

Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment

Fineline Cube Jul 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies

Fineline Cube Jul 30, 2024

Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Medical Device

ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First

Fineline Cube Jul 30, 2024

Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s...

Company Deals

Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia

Fineline Cube Jul 30, 2024

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture...

Company Drug

Organon’s Liptruzet Launches in China for Hypercholesterolemia Treatment

Fineline Cube Jul 30, 2024

US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet...

Company Deals

LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline

Fineline Cube Jul 30, 2024

LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...

Company Medical Device

Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device

Fineline Cube Jul 30, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...

Company Deals

Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion

Fineline Cube Jul 30, 2024

Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...

Policy / Regulatory

China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets

Fineline Cube Jul 30, 2024

The Ministry of Industry and Information Technology (MIIT) has released a report on the first...

Policy / Regulatory

China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results

Fineline Cube Jul 30, 2024

The National Health Commission (NHC) of China has released a notice detailing the results of...

Company Drug

EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi

Fineline Cube Jul 29, 2024

Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...

Policy / Regulatory

Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement

Fineline Cube Jul 29, 2024

Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment...

Company Drug

Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment

Fineline Cube Jul 29, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...

Company

AstraZeneca Charts Comprehensive Anti-Obesity Strategy with GLP-1 and Amylin Therapies

Fineline Cube Jul 29, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has outlined its strategic advancements and future...

Company

Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment

Fineline Cube Jul 29, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of...

Posts pagination

1 … 282 283 284 … 626

Recent updates

  • Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development
  • Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint
  • SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic
  • Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH
  • Pharscin Pharma’s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval – First Class 1.1 Innovative Drug Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Company Drug

SinoMab’s First‑in‑Class IL‑25R Antibody SM17 Wins NMPA IND Approval – Novel IBD Therapy Enters Clinic

Company Drug

Hengrui’s ANGPTL3 Antibody SHR-1918 NDA Accepted by NMPA – Priority Review for Rare Disease HoFH

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.